Results 81 to 90 of about 81,306 (284)

Oxaliplatin-induced immune pancytopenia

, 2005
BACKGROUND: Oxaliplatin, a third-generation platinum compound, has been implicated in isolated cases of immune hemolytic anemia and/or immune thrombocytopenia. The first case of severe immune pancytopenia related to oxaliplatin is described. PATIENT
Meyer, Oliver, Bomer, Markus M., Ahrens, Norbert, Taleghani, Behrouz Mansouri, Salama, Abdulgabar, Fontana, Stefano, Novak, Urban   +6 more
core   +1 more source

Characterizing oxaliplatin-resistant HCT116 cells.

, 2023
A) Dose-response curves of cell viability in the parental HCT116 cells, HCT116/OX-R4.3, and HCT116/OX-R10 cells treated with various concentrations of oxaliplatin. B) The survival fraction of cells treated with 0.1–60 μM oxaliplatin.
Zarrin Minuchehr (482407), Razieh Jalal (16747819), Tayebeh Cheraghi-shavi (16747816)   +2 more
core   +1 more source

One‐Year Changes in Frailty Components After Curative Minimally Invasive Surgery for Colorectal Cancer in Older Patients

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Frailty predicts outcomes after colorectal cancer surgery, but postoperative changes remain unclear. We previously reported improvement in FRAIL Scale‐based frail/pre‐frail status 1 year after curative minimally invasive surgery (MIS).
Hajime Ushigome, Takuya Suzuki, Shunsuke Hayakawa, Akira Kato, Yushi Yamakawa, Kenta Saito, Hiroyuki Sagawa, Ryo Ogawa, Hiroki Takahashi, Shuji Takiguchi   +9 more
wiley   +1 more source

Oxaliplatin rechallenge in patients with metastatic colorectal cancer prior treatment with oxaliplatin.

, 2015
785 Background: With limited number of available cytotoxic agents for the treatment of metastatic colorectal cancer (mCRC) patients (pts), rechallenge of chemotherapy can be considered for continuum of treatment.
Yong Sang Hong, Jeong-Eun Kim, Jae-Lyun Lee, Kyu-Pyo Kim, Tae Won Kim, Seong Joon Park   +5 more
core   +1 more source

Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long‐Term Survival

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy.
Ryosuke Fukushima, Kenichiro Araki, Ryo Muranushi, Kouki Hoshino, Kei Hagiwara, Shunsuke Kawai, Mariko Tsukagoshi, Takamichi Igarashi, Norio Kubo, Ken Shirabe   +9 more
wiley   +1 more source

Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles.

PLoS ONE, 2015
The platinum-based anticancer drug oxaliplatin is important clinically in cancer treatment. However, the role of multidrug resistance-associated protein 2 (MRP2) in controlling oxaliplatin membrane transport, in vivo handling, toxicity and therapeutic ...
Khine Myint, Yan Li, James Paxton, Mark McKeage   +3 more
doaj   +1 more source

Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions

Journal of the Formosan Medical Association, 2010
Hypersensitivity reactions during oxaliplatin infusion are a major problem associated with its use. In this study, we investigated the characteristics and risk factors of these events.
Yu-Yun Shao, Fu-Chang Hu, Jin-Tung Liang, Wen-Tzu Chiu, Ann-Lii Cheng, Chih-Hsin Yang   +5 more
doaj   +1 more source

Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue

, 2009
Background: Oxaliplatin and related chemotherapeutic drugs cause painful chronic peripheral neuropathies in cancer patients. We investigated changes in neuronal size profiles and neurofilament immunoreactivity in L5 dorsal root ganglion (DRG) tissue of
Subramaniam, J (15583175), Jong, NN (15576410), McKeage, MJ (15576416), Johnson Liu (14742571), Jamieson, SMF (15583178), Connor, B (15583181)   +5 more
core  

Oxaliplatin Treatment Alters Systemic Immune Responses [PDF]

, 2019
PURPOSE: Oxaliplatin is a platinum-based chemotherapeutic agent demonstrating significant antitumor efficacy. Unlike conventional anticancer agents which are immunosuppressive, oxaliplatin has the capacity to stimulate immunological effects in response ...
Apostolopoulos, Vasso, Stojanovska, V, Nurgali, K, Prakash, Monica, McQuade, R, Fraser, Sarah, Prakash, M, Fraser, S, Apostolopoulos, V, Nurgali, Kulmira, Stojanovska, Vanesa, McQuade, Rachel, Sakkal, Samy, Sakkal, S   +13 more
core   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita, Takeru Matsuda, Junko Mukohyama, Ryohei Sasaki, Yoshihiro Kakeji   +4 more
wiley   +1 more source